High factor VIII levels and anticoagulation - Medscape
2000年8月16日 · Previous studies have suggested high factor VIII levels are a risk factor for venous thromboembolism. Now, in a prospective study, Austrian researchers have found an almost 7-fold increase in the ...
Factor VIII Levels After Stroke May Flag Recurrent Events - Medscape
2013年10月18日 · Elevated Factor VIII. The investigators identified 206 patients with AIS in the Stroke Program registry from 2008 to 2012. Of these, 132 (64.1%) had elevated factor VIII at admission.
EMA Approves Factor VIII Deficiency Clotting Drug - Medscape
2024年4月26日 · The active substance of Altuvoct is efanesoctocog alfa, a recombinant human factor VIII, which replaces the missing coagulation factor VIII needed for effective hemostasis. Suitable for Adults and ...
Patient Is Clotting: What Do You Mean, the aPTT Is Prolonged?
2013年2月21日 · Factor VIII (hemophilia A) and IX (hemophilia B) deficiencies are sex-linked, and factor XI deficiency is autosomal recessive. (Hemophilia A may occur without a family history because the factor ...
FDA Clears First Long-Acting Hemophilia A Drug (Eloctate)
2014年6月9日 · Eloctate fuses coagulation factor VIII to the Fc protein fragment, which prolongs circulation in the body. "The therapy offers people with hemophilia A the potential to extend the interval between ...
Hympavzi Recommended for Approval in Europe for Severe
2024年9月20日 · Participants received marstacimab during a 12-month active treatment period vs standard care involving routine prophylaxis and an on-demand intravenous regimen with factor VIII or factor IX over a ...
FDA Approves Pfizer's Hympavzi for Hemophilia A, B - Medscape
2024年10月11日 · Hympavzi is the first non-factor, once-weekly treatment for hemophilia B in the United States. The subcutaneous injection emicizumab (Hemlibra, Genentech), which works by a different mechanism, is ...
Evidence-Based Treatment Recommendations for Uremic Bleeding
[19,73] Although the clinical effect of larger vWF–factor-VIII multimers is not well known, there is a strong association between their presence and shortening of bleeding time ( Table 4). [19 ...
VTE Prophylaxis in Patients With Cirrhosis and Coagulopathy
Levels of two procoagulants, factor VIII and von Willebrand factor, are actually increased in patients with cirrhosis; as von Willebrand factor promotes platelet migration and attachment to the ...
Evidence-Based Treatment Recommendations for Uremic Bleeding
Cryoprecipitate, rich in factor VIII, vWF and fibrinogen, should be reserved for patients who are either actively bleeding or in need of urgent surgery. It is also an important treatment option ...